CU20110020A7 - Compuestos de fenantrenona, composiciones y métodos - Google Patents

Compuestos de fenantrenona, composiciones y métodos

Info

Publication number
CU20110020A7
CU20110020A7 CU20110020A CU20110020A CU20110020A7 CU 20110020 A7 CU20110020 A7 CU 20110020A7 CU 20110020 A CU20110020 A CU 20110020A CU 20110020 A CU20110020 A CU 20110020A CU 20110020 A7 CU20110020 A7 CU 20110020A7
Authority
CU
Cuba
Prior art keywords
compounds
fenantrenone
compositions
methods
salts
Prior art date
Application number
CU20110020A
Other languages
English (en)
Other versions
CU23983B1 (es
Inventor
Paul Vincent Rucker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20110020A7 publication Critical patent/CU20110020A7/es
Publication of CU23983B1 publication Critical patent/CU23983B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se dirige a los compuestos de fórmula I: ESPACIO PARA LA FÓRMULA o sus sales, que son moduladores del receptor glucocorticoide. Los compuestos y sales de la invención son útiles en el tratamiento de afecciones mediadas por la actividad del receptor glucocorticoide.
CU2011000020A 2008-07-28 2011-01-28 Compuestos de fenantrenona CU23983B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8409508P 2008-07-28 2008-07-28
PCT/IB2009/053044 WO2010013158A1 (en) 2008-07-28 2009-07-14 Phenanthrenone compounds, compositions and methods

Publications (2)

Publication Number Publication Date
CU20110020A7 true CU20110020A7 (es) 2011-12-28
CU23983B1 CU23983B1 (es) 2014-03-26

Family

ID=41037773

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000020A CU23983B1 (es) 2008-07-28 2011-01-28 Compuestos de fenantrenona

Country Status (38)

Country Link
US (2) US8148409B2 (es)
EP (1) EP2307375B1 (es)
JP (1) JP4823397B1 (es)
KR (1) KR101377860B1 (es)
CN (1) CN102112446B (es)
AP (1) AP2744A (es)
AR (1) AR072535A1 (es)
AU (1) AU2009278029B2 (es)
BR (1) BRPI0917212A2 (es)
CA (1) CA2729578C (es)
CL (1) CL2011000141A1 (es)
CO (1) CO6290761A2 (es)
CR (1) CR20110012A (es)
CU (1) CU23983B1 (es)
DK (1) DK2307375T3 (es)
DO (1) DOP2011000029A (es)
EA (1) EA018024B1 (es)
EC (1) ECSP11010795A (es)
ES (1) ES2527137T3 (es)
GE (1) GEP20125640B (es)
GT (1) GT201100026A (es)
HR (1) HRP20150021T1 (es)
IL (1) IL210492A (es)
MA (1) MA32512B1 (es)
MX (1) MX2011001053A (es)
NI (1) NI201100028A (es)
NZ (1) NZ590559A (es)
PE (1) PE20110559A1 (es)
PL (1) PL2307375T3 (es)
PT (1) PT2307375E (es)
RS (1) RS53747B1 (es)
SI (1) SI2307375T1 (es)
SV (1) SV2011003821A (es)
TW (1) TWI374878B (es)
UA (1) UA99198C2 (es)
UY (1) UY32011A (es)
WO (1) WO2010013158A1 (es)
ZA (1) ZA201101520B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012229952A1 (en) * 2011-03-15 2013-04-18 Abbvie Inc. Nuclear hormone receptor modulators
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1542A (en) 1999-04-30 2006-01-31 Pfizer Prod Inc Glucocorticoid receptor modulators.
CA2379650C (en) 1999-07-30 2008-09-02 Eisai Co., Ltd. Process for producing a basic antibiotic inorganic acid salt, and oxalate intermediate
EP1201649B1 (en) 2000-10-28 2006-05-31 Pfizer Products Inc. Glucocorticoid receptor modulators
DE60113032T2 (de) 2000-10-30 2006-07-06 Pfizer Products Inc., Groton Glukokortikoidrezeptor-Modulatoren
AU2003281355A1 (en) * 2002-07-08 2004-01-23 Pfizer Products Inc. Modulators of the glucocorticoid receptor
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
EP2420505A1 (en) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
CA2671737A1 (en) 2006-12-05 2008-06-12 Neurogesx, Inc. Prodrugs and methods of making and using the same
EP2114888B1 (en) * 2007-02-02 2010-11-10 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
ATE518872T1 (de) * 2007-02-02 2011-08-15 Pfizer Prod Inc Trizyklische verbindungen und deren verwendung als glucocorticoidrezeptormodulatoren

Also Published As

Publication number Publication date
NZ590559A (en) 2011-09-30
EA201100080A1 (ru) 2011-08-30
DOP2011000029A (es) 2014-07-31
UY32011A (es) 2010-02-26
UA99198C2 (ru) 2012-07-25
TWI374878B (en) 2012-10-21
US20100069444A1 (en) 2010-03-18
IL210492A0 (en) 2011-03-31
HK1154245A1 (en) 2012-04-13
AU2009278029A1 (en) 2010-02-04
AR072535A1 (es) 2010-09-01
SI2307375T1 (sl) 2015-02-27
MX2011001053A (es) 2011-04-21
RS53747B1 (sr) 2015-06-30
KR20110022091A (ko) 2011-03-04
JP2011529103A (ja) 2011-12-01
MA32512B1 (fr) 2011-07-03
SV2011003821A (es) 2011-07-28
HRP20150021T1 (xx) 2015-03-27
US8552035B2 (en) 2013-10-08
CU23983B1 (es) 2014-03-26
ES2527137T3 (es) 2015-01-21
IL210492A (en) 2015-04-30
EP2307375B1 (en) 2014-11-19
US20120157502A1 (en) 2012-06-21
KR101377860B1 (ko) 2014-03-25
TW201014823A (en) 2010-04-16
AU2009278029B2 (en) 2012-05-03
ECSP11010795A (es) 2011-02-28
CA2729578C (en) 2014-05-27
PE20110559A1 (es) 2011-08-06
EP2307375A1 (en) 2011-04-13
DK2307375T3 (en) 2014-12-08
CL2011000141A1 (es) 2011-06-17
NI201100028A (es) 2011-08-05
BRPI0917212A2 (pt) 2015-11-10
CN102112446B (zh) 2012-10-31
GT201100026A (es) 2013-12-10
ZA201101520B (en) 2011-10-26
US8148409B2 (en) 2012-04-03
CN102112446A (zh) 2011-06-29
WO2010013158A1 (en) 2010-02-04
CR20110012A (es) 2011-02-10
AP2744A (en) 2013-09-30
PT2307375E (pt) 2015-01-14
JP4823397B1 (ja) 2011-11-24
GEP20125640B (en) 2012-09-10
PL2307375T3 (pl) 2015-03-31
CA2729578A1 (en) 2010-02-04
EA018024B1 (ru) 2013-04-30
AP2011005562A0 (en) 2011-02-28
CO6290761A2 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
CU23824A3 (es) Compuestos tricíclicos y sus composiciones
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO7400867A2 (es) Modificador del sabor dulce
CO6361937A2 (es) Derivados de heteroaril amidas y sus usos como activadores de glucoquinasa
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CR11871A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3- dioxigenasa
DOP2010000183A (es) Derivados de itazol usados como inhibidores de pi 3-cinasa
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CO6321288A2 (es) Sales de compuestos inhibidores de vih
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
CU20110020A7 (es) Compuestos de fenantrenona, composiciones y métodos
CU20080116A7 (es) 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas
DOP2009000191A (es) Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides
CU20100127A7 (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
UY30887A1 (es) Compuestos triciclicos, composiciones y procedimientos
CU20110054A7 (es) Derivados heteroaril amida y sus usos como glucoquinasa activadores
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3

Legal Events

Date Code Title Description
FG Grant of patent